THE SINGLE BEST STRATEGY TO USE FOR AGO TUMOR

Molecular typing is predicated on molecular genetic screening and isn't nevertheless routinely offered. Molecular subtypes and immunohistochemical surrogate markers on the tumors (HR, HER2, triple detrimental) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 may be valuable,